Boston Advisors LLC lowered its stake in Cambrex Corp. (NYSE:CBM) by 16.5% during the second quarter, Holdings Channel reports. The institutional investor owned 11,272 shares of the company’s stock after selling 2,225 shares during the period. Boston Advisors LLC’s holdings in Cambrex Corp. were worth $583,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in CBM. Bayesian Capital Management LP bought a new stake in Cambrex Corp. during the first quarter valued at about $276,000. Aperio Group LLC boosted its stake in Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock valued at $333,000 after buying an additional 221 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Cambrex Corp. by 15.7% in the first quarter. Glenmede Trust Co. NA now owns 11,888 shares of the company’s stock valued at $522,000 after buying an additional 1,612 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Cambrex Corp. by 106.5% in the second quarter. BNP Paribas Arbitrage SA now owns 10,385 shares of the company’s stock valued at $537,000 after buying an additional 5,356 shares in the last quarter. Finally, Capstone Asset Management Co. boosted its stake in Cambrex Corp. by 11.8% in the second quarter. Capstone Asset Management Co. now owns 13,070 shares of the company’s stock valued at $676,000 after buying an additional 1,380 shares in the last quarter. 99.46% of the stock is currently owned by institutional investors.
Cambrex Corp. (NYSE:CBM) traded up 0.55% on Tuesday, reaching $45.47. 247,832 shares of the company traded hands. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of 22.99 and a beta of 1.57. Cambrex Corp. has a 52-week low of $29.50 and a 52-week high of $59.41. The firm has a 50 day moving average price of $44.96 and a 200 day moving average price of $47.84.
Cambrex Corp. (NYSE:CBM) last issued its earnings results on Thursday, July 28th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.09. The business earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. Cambrex Corp. had a return on equity of 24.86% and a net margin of 13.97%. Cambrex Corp.’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. Equities research analysts predict that Cambrex Corp. will post $2.56 EPS for the current year.
Separately, Zacks Investment Research raised shares of Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $55.00 target price on the stock in a research report on Wednesday, August 3rd.
In related news, Director William B. Korb sold 3,420 shares of the company’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $55.00, for a total value of $188,100.00. Following the completion of the transaction, the director now directly owns 23,982 shares in the company, valued at $1,319,010. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.63% of the stock is owned by corporate insiders.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.